1875 Stock Overview
An investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
TOT BIOPHARM International Company Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.74 |
| 52 Week High | HK$2.79 |
| 52 Week Low | HK$1.48 |
| Beta | 0.20 |
| 11 Month Change | -12.12% |
| 3 Month Change | -3.87% |
| 1 Year Change | -3.33% |
| 33 Year Change | -58.17% |
| 5 Year Change | -66.47% |
| Change since IPO | -72.20% |
Recent News & Updates
We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation
Jun 07
The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More
May 21Recent updates
We Think Some Shareholders May Hesitate To Increase TOT BIOPHARM International Company Limited's (HKG:1875) CEO Compensation
Jun 07The Market Lifts TOT BIOPHARM International Company Limited (HKG:1875) Shares 29% But It Can Do More
May 21Is TOT BIOPHARM International (HKG:1875) Using Debt In A Risky Way?
Mar 18There's No Escaping TOT BIOPHARM International Company Limited's (HKG:1875) Muted Revenues
Dec 28Does TOT BIOPHARM International (HKG:1875) Have A Healthy Balance Sheet?
Nov 23We Think TOT BIOPHARM International (HKG:1875) Has A Fair Chunk Of Debt
May 18Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation
Jul 27An Intrinsic Calculation For TOT BIOPHARM International Company Limited (HKG:1875) Suggests It's 41% Undervalued
Mar 26Here's Why We're Watching TOT BIOPHARM International's (HKG:1875) Cash Burn Situation
Feb 03Shareholder Returns
| 1875 | HK Biotechs | HK Market | |
|---|---|---|---|
| 7D | 2.4% | -2.1% | -6.4% |
| 1Y | -3.3% | -12.5% | 9.5% |
Return vs Industry: 1875 exceeded the Hong Kong Biotechs industry which returned -13.4% over the past year.
Return vs Market: 1875 underperformed the Hong Kong Market which returned 10.4% over the past year.
Price Volatility
| 1875 volatility | |
|---|---|
| 1875 Average Weekly Movement | 6.8% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 9.0% |
| 10% most volatile stocks in HK Market | 18.9% |
| 10% least volatile stocks in HK Market | 4.2% |
Stable Share Price: 1875 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 1875's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | 572 | Jun Liu | www.totbiopharm.com |
TOT BIOPHARM International Company Limited, an investment holding company, engages in the research, development, manufacturing, and marketing of anti-tumor drugs in China. The company develops and markets Pusintin, a bevacizumab injection for the treatment of non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; cervical cancer; and hepatocellular carcinoma. It also offers Tazian, a temozolomide capsule for the treatment of glioblastoma multiforme or anaplastic astrocytoma; and Megaxia, a megestrol acetate oral suspension for the treatment of anorexia associated with acquired immunode¬ciency syndrome, as well as signi¬cant weight loss of AIDS and cancer patients caused by cachexia.
TOT BIOPHARM International Company Limited Fundamentals Summary
| 1875 fundamental statistics | |
|---|---|
| Market cap | HK$1.34b |
| Earnings (TTM) | HK$9.63m |
| Revenue (TTM) | HK$1.05b |
139.6x
P/E Ratio1.3x
P/S RatioIs 1875 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1875 income statement (TTM) | |
|---|---|
| Revenue | CN¥973.17m |
| Cost of Revenue | CN¥272.28m |
| Gross Profit | CN¥700.89m |
| Other Expenses | CN¥691.93m |
| Earnings | CN¥8.97m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.012 |
| Gross Margin | 72.02% |
| Net Profit Margin | 0.92% |
| Debt/Equity Ratio | 52.9% |
How did 1875 perform over the long term?
See historical performance and comparison